Pages that link to "Q34083131"
Jump to navigation
Jump to search
The following pages link to A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck (Q34083131):
Displaying 50 items.
- Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors (Q26750719) (← links)
- Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC) (Q26765429) (← links)
- HER2 as a therapeutic target in head and neck squamous cell carcinoma (Q27026178) (← links)
- Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial (Q27853153) (← links)
- Toward the use of precision medicine for the treatment of head and neck squamous cell carcinoma (Q28074691) (← links)
- Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (Q33650470) (← links)
- Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study (Q33653707) (← links)
- Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy (Q33839177) (← links)
- Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized c (Q34896542) (← links)
- Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib (Q35807946) (← links)
- Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo (Q35822882) (← links)
- miR-124 Regulates the Epithelial-Restricted with Serine Box/Epidermal Growth Factor Receptor Signaling Axis in Head and Neck Squamous Cell Carcinoma (Q36132797) (← links)
- Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck (Q36371601) (← links)
- Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions. (Q36383018) (← links)
- Afatinib reverses multidrug resistance in ovarian cancer via dually inhibiting ATP binding cassette subfamily B member 1. (Q36413392) (← links)
- A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma (Q36447729) (← links)
- In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma (Q36766842) (← links)
- Trends in chemoradiation use in elderly patients with head and neck cancer: Changing treatment patterns with cetuximab (Q37146157) (← links)
- Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung. (Q38514601) (← links)
- Pharmacotherapy of head and neck cancer (Q38619293) (← links)
- Afatinib in squamous cell carcinoma of the head and neck (Q38829891) (← links)
- Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives. (Q38838071) (← links)
- Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies (Q38851114) (← links)
- Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck (Q38892486) (← links)
- Systemic Treatment in HPV-Induced Recurrent or Metastatic HNSCC. (Q38971558) (← links)
- Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study). (Q39187965) (← links)
- Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. (Q39193035) (← links)
- Afatinib down-regulates MCL-1 expression through the PERK-eIF2α-ATF4 axis and leads to apoptosis in head and neck squamous cell carcinoma (Q40970957) (← links)
- Visualization of early prostatic adenocarcinoma as a stem cell disease (Q41851423) (← links)
- Ultra High Performance Liquid Chromatography Method for the Determination of Two Recently FDA Approved TKIs in Human Plasma Using Diode Array Detection (Q42625287) (← links)
- Personalized Medicine Approach for an Exceptional Response to Multiple-recurrent and Metastatic HER2-positive Oropharyngeal Squamous Cell Carcinoma (Q44846795) (← links)
- Genomic alterations in human epidermal growth factor receptor 2 (HER2/ERBB2) in head and neck squamous cell carcinoma (Q45408645) (← links)
- EGFR-targeted therapies in the post-genomic era. (Q45871491) (← links)
- Emerging drugs for head and neck cancer (Q45874449) (← links)
- Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer (Q46738588) (← links)
- Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus-associated oropharyngeal squamous cell cancer. (Q47722276) (← links)
- Discovering drugs to overcome chemoresistance in ovarian cancers based on the cancer genome atlas tumor transcriptome profile. (Q49220207) (← links)
- Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review (Q50021063) (← links)
- Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2. (Q50026716) (← links)
- Leveraging Genomics for Head and Neck Cancer Treatment (Q50116331) (← links)
- Effects of neratinib and combination with irradiation and chemotherapy in head and neck cancer cells. (Q51603922) (← links)
- Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines. (Q52617485) (← links)
- Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma. (Q54979771) (← links)
- Blocking of the EGFR-STAT3 signaling pathway through afatinib treatment inhibited the intrahepatic cholangiocarcinoma. (Q55364953) (← links)
- Appropriate Sequence for Afatinib and Cisplatin Combination Improves Anticancer Activity in Head and Neck Squamous Cell Carcinoma (Q57818008) (← links)
- An update: emerging drugs to treat squamous cell carcinomas of the head and neck (Q58095080) (← links)
- Multidisciplinary Management of Hypopharyngeal Carcinoma (Q58863205) (← links)
- Good local tumor control but lethal hemorrhage after apatinib treatment for intractable squamous carcinoma of the floor of the mouth: a case report (Q60045934) (← links)
- Meta-analysis of the effects of anti-epidermal growth factor receptor on recurrent/metastatic head and neck squamous cell carcinoma (Q61455699) (← links)
- Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer (Q61814976) (← links)